5 episodes of timely health info. uploaded to YouTube. Check this out every month at this YouTube channel!

Textbook publication by our very own Dr. Jane Nwazue

The 2nd Annual Convention of the Abia State University Medical Alumni Association, UK

London 2017 - Live Coverage

Theddeus Iheanacho, Yale Assistant Professor of Psychiatry delivering a lecture @ The 2nd Annual ABSU Medical Alumni, UK, London 2017 Convention.
Pioneer Provost, Professor F.C Akpuaka @ the 2017 ABSU Medical Alumni, UK Convention.
Dr. Collins Iwuji @ the 2017 ABSU Medical Alumni, UK Convention.




Theme: Efficient and Cost Effective Healthcare.    

Date: Sunday 30th April 2017  

Venue: Doubletree by Hilton Hotel Dartford Bridge,  Crossways Business Park, Masthead Close,  Dartford, London, DA2 6QF.  



Free month-long major Surgical outreach in the month of April, 2017

The department of Surgery, Abia State University Teaching Hospital (ABSUTH) Aba, is embarking on a Free month-long major Surgical outreach in the month of April, 2017.

This program is courtesy of the approval by Dr. Okezie Victor Ikpeazu, the Governor of Abia State, to assist the poor and indigent members of the State.

People with serious health issues requiring surgical intervention are advised to immediately report to the Teaching Hospital for preliminary procedures that will enable them participate in the Free Surgery program.

Signed: Prof. Chuks Kamanu, CMD.

Disease Outbreak News

Ebola virus disease - EVD

Ebola virus disease – Democratic Republic of the Congo: Disease outbreak news.
REPORT: from World Health Organization
Published on 13 May 2017
On 9 May 2017, WHO was informed of a cluster of undiagnosed illness and deaths including haemorrhagic symptoms in Likati Health Zone, Bas Uele Province in the north of the Democratic Republic of the Congo (DRC), bordering Central African Republic. Since 22 April, nine cases including three deaths have been reported. Six cases are currently hospitalized.
On 11 May 2017, the Ministry of Health (MoH) of DRC informed WHO that of the five samples collected from suspected cases, one tested positive by RT-PCR for Ebola virus subtype Zaire at the Institut National de Recherche Biomédicale (INRB) in Kinshasa. Additional specimens are currently being tested and results, including sequencing, are awaited to describe the outbreak.
On 10 May 2017, a multidisciplinary team led by the MoH and supported by WHO and partners was deployed to the field and are expected to reach the affected area on 12 or 13 May 2017 to conduct an in depth field investigation.
The investigation is currently ongoing and information is available for only three of the suspected cases: The first case (and possibly the index case), a 39-year-old male presented onset of symptoms on 22 April 2017 and deceased on arrival at the health facility. He presented with haematuria, epistaxis, bloody diarrhoea, and haematemesis. Two contacts of this case are being investigated: a person who took care of him during transport to the health care facility (he has since developed similar symptoms) and a moto-taxi driver (deceased) who transported the patient to the health care facility.
Personal Protective Equipment (PPE) for health care workers has been shipped on 12 May 2017 to Kisangani. Additional kits are currently being prepared and will be shipped as soon as available.
Background and epidemiological situation
On 20 November 2014, as per WHO recommendations, the MoH of DRC and WHO declared the end of the EVD outbreak that started on 24 August 2014 and resulted in a total of 38 laboratory confirmed cases and 28 probable case including 49 deaths in Boende, Equateur province. This was the seventh outbreak of EVD since its discovery in 1976 in DRC.
2014: 66 cases of EVD including 49 deaths diagnosed initially in Equateur province (Watsi Kengo, Lokolia, Boende, and Boende Muke).
2012: 36 cases including 13 deaths Orientale province - Isiro (Bundibugyo virus).
2008–2009: 32 cases including 15 deaths in Kasaï-Occidental (Zaire virus).
2007: 264 cases including 187 deaths in Kasaï-Occidental (Zaire virus).
1995: 315 cases and 250 deaths occurred in Kikwit and surrounding area.
1977: 1 case (Zaire virus).
1976: 318 cases including 280 deaths in Yambuku (Zaire virus).
There are five identified subtypes of Ebola virus. The subtypes have been named after the location where they have been first detected. Three of the five subtypes have been associated with large Ebola haemorrhagic fever (EHF) outbreaks in Africa. Ebola–Zaire, Ebola–Sudan and Ebola–Bundibugyo. EHF is a febrile haemorrhagic illness which causes death in 25–90% of all cases.
Public health response
The following public health response measures have been implemented:
The national committee against viral haemorrhagic fever has been reactivated and will continue meeting every day to coordinate the response. Strengthening of surveillance and investigation including contact tracing are ongoing. WHO will provide assistance and technical support. The deployment to DRC of an additional WHO multidisciplinary team is currently considered to support the response of national authorities. The Global Outbreak Alert and Response Network (GOARN) has been activated to provide additional support if required. The need an feasibility of potential Ebola ring vaccination is being discussed.
WHO risk assessment
To date, the outbreak is reported in a remote and hard to reach area and appears to be geographically relatively limited. However, Investigations are ongoing to assess the full extent of the outbreak and therefore high vigilance still needs to be maintained.
WHO does not recommend any restriction of travel and trade to DRC based on the currently available information.

Antimicrobial Resistance

Pfizer Inc. today announced the launch of ATLAS

Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries. Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance. To that end, ATLAS can not only help physicians select the most appropriate treatment choices for their patients, but also enable global health authorities to develop data-driven antimicrobial resistance mitigation strategies. Pfizer will formally unveil ATLAS on April 22nd at the annual meeting of the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna.

“ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilization of antibiotics and improve infection prevention and control.”
Tweet this
Mobile devices and applications provide many benefits for healthcare professionals including increased access to point of care tools, which have been shown to support better clinical decision making and improved patient outcomes. In response to this need, Pfizer also offers ATLAS as a mobile application to enable rapid access to important resistance information at the point of patient care.

ATLAS offers an interactive platform that enables physicians to evaluate data, conduct analyses, and export tables and figures that include parameters such as pathogen, region, specimen source and in vitro susceptibility data. The ATLAS database is updated every six months with new resistance data from healthcare institutions in more than 60 countries as these become available. ATLAS can be accessed by visiting:

“An important aspect for physicians when treating patients is knowledge; knowledge of where certain resistant bacterial infections tend to occur and knowledge of which antibiotics remain effective against them,” said Dr. Freda Lewis-Hall, Chief Medical Officer of Pfizer Inc. “ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilization of antibiotics and improve infection prevention and control.”

About Antimicrobial Resistance (AMR)

The World Health Organization (WHO) characterizes antimicrobial resistance as one of the biggest threats to global health, that can affect anyone at any age in any country, threatening our ability to treat serious infections and provide standard medical procedures. Gram-negative bacteria, the cause of many healthcare-associated infections (HAIs), have become increasingly resistant to many available antibiotic treatments. These infections are associated with increased patient mortality and cost of care. At present, approximately 700,000 deaths per year are attributed to antimicrobial resistance globally, with an increase to 10 million predicted by 2050 if no action is taken to address this issue.

About Pfizer’s Commitment to Antimicrobial Resistance:

Today, Pfizer is the leading global provider of anti-infective medicines in the industry, offering patients access to a diverse portfolio of more than 80 products. Pfizer recognizes the serious public health threat associated with AMR and has taken significant steps to address this issue. In early 2016, Pfizer was a signatory of the Declaration on Combating Antimicrobial Resistance (AMR), a global call-to-action drafted and signed by more than 100 companies and 13 trade associations encouraging greater industry and government collaboration to address the issue of antimicrobial resistance. As a follow-up to the AMR Declaration, Pfizer and 13 industry partners unveiled the “Industry Roadmap to Combat Antimicrobial Resistance,” a comprehensive plan of action, that lays out four key commitments we pledge to deliver by 2020. For more information on Pfizer’s commitment to AMR, please click here.

About Pfizer Anti-Infectives

Since its pioneering work on penicillin in the 1940s, Pfizer has been actively engaged in the research and development of innovative medicines, policies and educational programs to address the evolving needs of patients and physicians in the area of infectious diseases.

For more than 30 years, Pfizer has been a leader in developing and implementing innovative public-private partnerships designed to address unmet medical needs and global public health issues. Today, our patient assistance programs expand access to potentially lifesaving medicines and provide educational resources that empower patients and physicians in the fight against infectious disease.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at